Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma (Q46423087)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 August 2008

Language	Label	Description	Also known as
English	Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma	scientific article published on 19 August 2008

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

author name string

Francesca Valcamonico

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

Vittorio Ferrari

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

Vito Amoroso

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

Giovanni Rangoni

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

Edda Simoncini

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

Patrizia Marpicati

6

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

Lucia Vassalli

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

Salvatore Grisanti

8

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

Giovanni Marini

9

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

publication date

19 August 2008

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

91

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

47-50

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712279

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712279

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712279

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712279

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712279

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712279

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712279

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712279

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712279

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712279

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complete cerebral response with sunitinib for metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712279

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib relieves renal cell carcinoma spinal cord compression

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712279

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-008-9676-4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18712279

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46423087&oldid=2207857706"